- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Resistant & Refractory Hypertension: 9 Questions for Primary Care
How are you managing your patients with resistant or refractory hypertension? How do your strategies align with current guidelines? Try these 9 questions and find out.
This quiz poses questions for primary care professionals on treating a condition defined by its resistance to prior treatment. Among the patients you see every day, the prevalence of hypertension is increasing with age. Estimates are that approximately 7% of US young adults aged 18–39 have hypertension. The prevalence increases more than 9-fold to 65% among those aged 60 and over. In your panel, are there individuals with persistent uncontrolled hypertension?
The questions are based on a Patient Care Guideline Topline that summarizes a review on assessment and management of resistant and refractory hypertension published in The American Journal of Medicine. Try the quiz first, then click through the Topline for a quick update.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
